Linked e-resources
Details
Table of Contents
About the Editor and Contributors; Chapter-1; Sustainable Development for the Health-Care Industry: Setting the Stage; Human Society Has Always Been Focused on Health; The Mission of the Health-Care Industry; The Life Cycle of Pharmaceutical Products; The Mega Trends Which Affect the Health-Care Industry; Societal Expectations for Personalized Medicine; The DNA of the Health-Care Industry: Evolving Management of Innovation; Sustainability and Pharmaceutical Products: Role in Human Health (Mistra Pharma 2009)
Pharmaceutical Products and Contribution to Global Health: Global Health Requires More than Better DrugsSustainable Concerns All Along the Life Cycle of the Health-care Industry; R&D; Manufacturing and Supply Chain; Licensing and Market Access; Consumption of Health-Care Products: Use, Access, and Disease Management; Global Corporate Governance; Conclusion; References; Chapter-2; Can Innovation Still Be the Main Growth Driver of the Pharmaceutical Industry?; Innovation as a Driver of Growth for the Pharmaceutical Industry in the Past; The Pharmaceutical Industry Today
The R&D Investments of Top Pharmaceutical CompaniesThe Output of Pharmaceutical R&D; The Pharmaceutical Innovation Process; The Success Rates of Pharmaceutical R&D; The Timelines of Pharmaceutical R&D; The Cost of Pharmaceutical R&D; A Steady-State R&D Model; The Reduced R&D Efficiency; Consequences of the Reduced R&D Efficiency; Increasing the Number of Projects in the R&D Pipeline; Reducing Costs of R&D; Measuring Performance and Managing the Project Portfolio Actively; Opening R&D Towards External Innovation; Sustainable Growth in Times of Reduced R&D Efficiency
Increasing Pressure from Generic DrugsSustainability Must Come from R&D; References; The Importance of Understanding the 'Lived Experience' of Patients in Pharmaceutical Development Programmes; Chapter-3; Introduction; How Can We Make Sure We Look Beyond the Science and Capture the 'Human Being' in Our Data?; Is the Pharmaceutical Industry Brave Enough to Let Patients Contribute to Driving the Research Agenda?; So How Do We Facilitate This?; How Can We Benefit From This Sort of Research?; Building the Value Chain With Patients Playing a Key Role; So What Can We Do to Drive Change?
Why Bother?Chapter-4; Listening to the Voice of the Patient to Facilitate Earlier Access to Promising Medicines: Interview with Sjaak Vink; Chapter-5; Drivers of the Real-World Data Revolution and the Transition to Adaptive Licensing: Interview with Dr. Richard Barker; CASMI (Center for the Advancement of Sustainable Medical Innovation); Chapter-6; Sustainable Development for the Healthcare Industry: Vantage Point from Emerging Economies; Introduction; Sustainable Commercialization; Roles Played by MNCs Versus Local Manufacturers in Emerging Economies; Vantage Point; Regulations
Pharmaceutical Products and Contribution to Global Health: Global Health Requires More than Better DrugsSustainable Concerns All Along the Life Cycle of the Health-care Industry; R&D; Manufacturing and Supply Chain; Licensing and Market Access; Consumption of Health-Care Products: Use, Access, and Disease Management; Global Corporate Governance; Conclusion; References; Chapter-2; Can Innovation Still Be the Main Growth Driver of the Pharmaceutical Industry?; Innovation as a Driver of Growth for the Pharmaceutical Industry in the Past; The Pharmaceutical Industry Today
The R&D Investments of Top Pharmaceutical CompaniesThe Output of Pharmaceutical R&D; The Pharmaceutical Innovation Process; The Success Rates of Pharmaceutical R&D; The Timelines of Pharmaceutical R&D; The Cost of Pharmaceutical R&D; A Steady-State R&D Model; The Reduced R&D Efficiency; Consequences of the Reduced R&D Efficiency; Increasing the Number of Projects in the R&D Pipeline; Reducing Costs of R&D; Measuring Performance and Managing the Project Portfolio Actively; Opening R&D Towards External Innovation; Sustainable Growth in Times of Reduced R&D Efficiency
Increasing Pressure from Generic DrugsSustainability Must Come from R&D; References; The Importance of Understanding the 'Lived Experience' of Patients in Pharmaceutical Development Programmes; Chapter-3; Introduction; How Can We Make Sure We Look Beyond the Science and Capture the 'Human Being' in Our Data?; Is the Pharmaceutical Industry Brave Enough to Let Patients Contribute to Driving the Research Agenda?; So How Do We Facilitate This?; How Can We Benefit From This Sort of Research?; Building the Value Chain With Patients Playing a Key Role; So What Can We Do to Drive Change?
Why Bother?Chapter-4; Listening to the Voice of the Patient to Facilitate Earlier Access to Promising Medicines: Interview with Sjaak Vink; Chapter-5; Drivers of the Real-World Data Revolution and the Transition to Adaptive Licensing: Interview with Dr. Richard Barker; CASMI (Center for the Advancement of Sustainable Medical Innovation); Chapter-6; Sustainable Development for the Healthcare Industry: Vantage Point from Emerging Economies; Introduction; Sustainable Commercialization; Roles Played by MNCs Versus Local Manufacturers in Emerging Economies; Vantage Point; Regulations